Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Boston Scientific (BSX) yesterday. The company’s shares closed last Thursday at $38.67.
According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 26.5% and a 68.6% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Edwards Lifesciences.
Boston Scientific has an analyst consensus of Moderate Buy, with a price target consensus of $42.69.
See today’s analyst top recommended stocks >>
The company has a one-year high of $42.37 and a one-year low of $24.10. Currently, Boston Scientific has an average volume of 11.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Read More on BSX:
